---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-028359"
form_type: "8-K"
ticker: "AIXC"
cik: "0001460702"
company_name: "AIxCrypto Holdings, Inc."
filed_at: "2024-07-18T23:59:59+00:00"
generated_at: "2026-05-31T19:37:13.198526+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Qualigen Therapeutics Advances $1.25 Million to Marizyme via Promissory Note at 18% Interest

## Summary
- Qualigen advanced $1,250,000 to Marizyme, Inc. on July 15, 2024, under a demand promissory note dated July 12, 2024.
- The note bears interest at 18% per annum and allows prepayment without premium or penalty.
- The agreement is disclosed under Item 1.01 of Form 8-K filed July 18, 2024, signed by CEO Michael S. Poirier.

## SEC filing metadata
- accession: 0001493152-24-028359
- form_type: 8-K
- ticker: AIXC
- cik: 0001460702
- company_name: AIxCrypto Holdings, Inc.
- filed_at: 2024-07-18T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1460702/000149315224028359/0001493152-24-028359-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1460702/000149315224028359/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-028359
- JSON: https://secwatch.observer/filing/0001493152-24-028359.json
- Plain text: https://secwatch.observer/filing/0001493152-24-028359.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.